Home > Qtrly Results > MANKIND PHARMA

MANKIND PHARMA
Quarterly Results Analysis [Mar2026]

MANKIND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best Quarterly Growth Mid Cap Stocks
Best 1M Momentum Mid Cap Stocks
COMMUNITY POLL
for MANKIND PHARMA
Please provide your vote to see the results

MANKIND PHARMA Quarterly Results

Consolidated Mar2026
UnAudited
Dec2025
UnAudited
Sep2025
UnAudited
Jun2025
UnAudited
Mar2025
UnAudited
Dec2024
UnAudited
Sep2024
UnAudited
Jun2024
UnAudited
Revenues ₹3,443 Cr ₹3,567 Cr ₹3,697 Cr ₹3,570 Cr ₹3,079 Cr ₹3,199 Cr ₹3,061 Cr ₹2,868 Cr
Expenses ₹2,513 Cr ₹2,648 Cr ₹2,776 Cr ₹2,724 Cr ₹2,396 Cr ₹2,383 Cr ₹2,214 Cr ₹2,196 Cr
Operating Income ₹930 Cr ₹919 Cr ₹921 Cr ₹847 Cr ₹683 Cr ₹816 Cr ₹847 Cr ₹672 Cr
Other Income ₹114 Cr ₹73 Cr ₹92 Cr ₹80 Cr ₹251 Cr ₹77 Cr ₹109 Cr ₹99 Cr
Interest ₹142 Cr ₹157 Cr ₹170 Cr ₹171 Cr ₹191 Cr ₹221 Cr ₹7 Cr ₹11 Cr
Depreciation ₹223 Cr ₹223 Cr ₹222 Cr ₹219 Cr ₹231 Cr ₹187 Cr ₹100 Cr ₹103 Cr
Profit Before Tax ₹656 Cr ₹506 Cr ₹622 Cr ₹537 Cr ₹513 Cr ₹485 Cr ₹849 Cr ₹657 Cr
Profit After Tax ₹556 Cr ₹411 Cr ₹518 Cr ₹441 Cr ₹427 Cr ₹374 Cr ₹659 Cr ₹535 Cr
EPS ₹13.43 ₹9.90 ₹12.39 ₹10.62 ₹10.20 ₹9.22 ₹16.31 ₹13.39
Industry Peers & Returns1W1M1Y
MANKIND PHARMA -0.6% 11% -1.8%
SUN PHARMACEUTICAL INDUSTRIES -3.2% 10.5% 9.3%
DIVIS LABORATORIES 0.8% 9.5% 4.2%
TORRENT PHARMACEUTICALS 2% 9.9% 35.4%
CIPLA -1.9% 13.3% -6%
DR REDDYS LABORATORIES -1.8% 7.4% 8.2%
LUPIN 1.2% -1.2% 12.7%
ZYDUS LIFESCIENCES 4.8% 11.8% 13.7%
AUROBINDO PHARMA -2.5% 3.1% 28.2%

MANKIND PHARMA Quarterly Revenues

Revenues
Q-o-Q

-3.48 %

Y-o-Y

11.81 %

Quarters Revenues % Change
Mar2026 ₹3,443 Cr
-3.48
Dec2025 ₹3,567 Cr
-3.52
Sep2025 ₹3,697 Cr
3.55
Jun2025 ₹3,570 Cr
15.94
Mar2025 ₹3,079 Cr
-3.73
Dec2024 ₹3,199 Cr
4.49
Sep2024 ₹3,061 Cr
6.75
Jun2024 ₹2,868 Cr -

MANKIND PHARMA Quarterly Operating Profit

Operating Profit
Q-o-Q

1.14 %

Y-o-Y

36.11 %

Quarters Operating Profit % Change
Mar2026 ₹930 Cr
1.14
Dec2025 ₹919 Cr
-0.21
Sep2025 ₹921 Cr
8.81
Jun2025 ₹847 Cr
23.94
Mar2025 ₹683 Cr
-16.27
Dec2024 ₹816 Cr
-3.68
Sep2024 ₹847 Cr
26.15
Jun2024 ₹672 Cr -
Operating Margins
Q-o-Q

4.81 %

Y-o-Y

21.72 %

Quarters Operating Margin% % Change
Mar2026 27.01%
4.81
Dec2025 25.77%
3.41
Sep2025 24.92%
5.06
Jun2025 23.72%
6.89
Mar2025 22.19%
-13.01
Dec2024 25.51%
-7.81
Sep2024 27.67%
18.15
Jun2024 23.42% -

MANKIND PHARMA Quarterly Profit After Tax

Profit After Tax(PAT)
Q-o-Q

35.49 %

Y-o-Y

30.41 %

Quarters Profit After Tax % Change
Mar2026 ₹556 Cr
35.49
Dec2025 ₹411 Cr
-20.70
Sep2025 ₹518 Cr
17.31
Jun2025 ₹441 Cr
3.46
Mar2025 ₹427 Cr
13.95
Dec2024 ₹374 Cr
-43.15
Sep2024 ₹659 Cr
23.22
Jun2024 ₹535 Cr -
PAT Margins
Q-o-Q

40.40 %

Y-o-Y

16.59 %

Quarters PAT Margin(%) % Change
Mar2026 16.16 %
40.40
Dec2025 11.51 %
-17.84
Sep2025 14.01 %
13.35
Jun2025 12.36 %
-10.82
Mar2025 13.86 %
18.36
Dec2024 11.71 %
-45.59
Sep2024 21.52 %
15.45
Jun2024 18.64 % -

MANKIND PHARMA Quarterly Earnings Per Share (EPS)

EPS
Q-o-Q

35.66 %

Y-o-Y

31.67 %

Quarters EPS % Change
Mar2026 ₹13.43
35.66
Dec2025 ₹9.9
-20.10
Sep2025 ₹12.39
16.67
Jun2025 ₹10.62
4.12
Mar2025 ₹10.2
10.63
Dec2024 ₹9.22
-43.47
Sep2024 ₹16.31
21.81
Jun2024 ₹13.39 -

You may also like the below Video Courses